ÂÜÀòÂÒÂ×

Mark Fereshteh currently serves as Vice President and Global Head of Precision Medicine at Genmab, a position held since January 2019, and has also held roles as Vice President of Translational Science and Clinical Biomarkers and Head of Translational Medicine in Oncology. Prior experience includes various positions at Bristol-Myers Squibb from July 2011 to 2018, culminating in Associate Director of Lead Discovery in Oncology, where Mark led efforts in Immuno Oncology. Academic contributions include a postdoctoral fellowship at Duke University, focusing on hematopoietic malignancies in renowned labs, as well as doctoral research at Georgetown University on tumor biology, particularly in breast and pancreatic cancers. Earlier professional experiences include significant roles in drug discovery at Bristol-Myers Squibb and DuPont Pharmaceuticals. Education consists of a PhD in Tumor Biology from Georgetown University and a postdoctoral fellowship in Pharmacology and Cancer Biology from Duke University.